Trial Profile

A phase I study of BCX-9250 for the treatment of Fibrodysplasia ossificans progressiva

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 04 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BCX 9250 (Primary)
Indications Fibrodysplasia ossificans progressiva
Focus Adverse reactions; First in man
Sponsors BioCryst Pharmaceuticals

Most Recent Events

26 Feb 2024 According to BioCryst Pharmaceuticals media release, BioCryst Pharmaceuticals announced in December 2022 and November 2022 regarding the discontinuation BCX9250 programs.
26 Feb 2024 Status changed from recruiting to discontinued as per BioCryst Pharmaceuticals media release.
31 Aug 2022 According to BioCryst Pharmaceuticals media release, data from this trial will be presented at American Society for Bone and Mineral Research Annual Meeting

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com